Before committing to a retatrutide research protocol, most researchers want a clear number: what will this actually cost, week by week? The figure changes substantially depending on which dose level you are working at — and the spread between a conservative low-dose protocol and a high-dose program is wide enough that it is worth mapping out before you order.
What the Phase 2 Trial Tells Us About Dose Selection
The reference point most researchers use is the Eli Lilly Phase 2 trial published in the New England Journal of Medicine (2023). [1] Four weekly dose groups were studied over 48 weeks, with clear dose-dependent outcomes:
- 2mg / week — mean body weight reduction of ~8.7%
- 4mg / week — mean body weight reduction of ~17.3%
- 8mg / week — mean body weight reduction of ~22.8%
- 12mg / week — mean body weight reduction of ~24.2%, with no plateau observed at week 48
These four dose groups are now the standard planning framework used in the research community. They also map directly onto how much vial supply a research program requires per month.
Vial Cost and Usable Quantity
Retatrutide from Aus Peptide Supply is supplied as a lyophilised powder at 10mg per vial, priced at $139.99 AUD. That full 10mg is the usable amount — there is no dead volume to account for at the vial level. All monthly cost estimates below derive from this baseline.
Monthly Supply Cost at Each Protocol Dose
The table below uses a standard four-week month and the four Phase 2 dose groups as reference. Every figure is calculated from a single 10mg vial at $139.99.
Monthly cost estimated as: (4 doses/month × weekly dose) ÷ 10mg × $139.99. Figures are for research planning reference only.
How the "Per Month" Frame Applies to Research
The monthly framing originates in the clinical world, where GLP-1 medications like Ozempic and Mounjaro are dispensed on monthly scripts. Retatrutide is not a prescription medication in Australia — it is a research compound available for in-vitro laboratory and research use only and is not for human consumption. That said, the monthly cost frame remains a practical way to structure research budgets, since multi-week protocols are typically planned and reviewed in four-week windows.
Multi-Vial Option for Low-Dose Researchers
Researchers working at the 2mg/week level have the most vial-efficient option available: the Retatrutide Starter Bundle at $269.99 AUD includes 2×10mg vials alongside bacteriostatic water, insulin syringes, and alcohol swabs. At 2mg weekly, two vials covers 10 weeks of research, and the bundle saves $35.97 compared to sourcing each item separately.
For researchers who have not reconstituted a peptide before, the bundle also removes the need to track down each consumable from separate suppliers.
Australian Domestic Supply
Every Retatrutide vial from Aus Peptide Supply is shipped domestically within Australia. No international freight, no customs uncertainty, no import duties. Each production batch is independently analysed with a Certificate of Analysis available by lot number.
References
- Jastreboff et al. — Triple Hormone Receptor Agonist (Retatrutide) for Obesity — A Phase 2 Trial, NEJM (2023)
- Lilly Press Release — TRIUMPH-4 Phase 3 Topline Results, December 2025
⚠ All information is for educational and research purposes only. Retatrutide is supplied for in-vitro research and laboratory use only. Not for human consumption.
